Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 11.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,790 shares of the biopharmaceutical company’s stock after acquiring an additional 3,430 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Agios Pharmaceuticals were worth $1,082,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $53,000. KBC Group NV raised its position in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares during the period. Quest Partners LLC boosted its holdings in Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Agios Pharmaceuticals during the third quarter valued at about $146,000.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Trading Up 3.4 %

AGIO opened at $31.99 on Tuesday. Agios Pharmaceuticals, Inc. has a twelve month low of $27.14 and a twelve month high of $62.58. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 2.82 and a beta of 0.90. The company has a fifty day simple moving average of $33.67 and a 200 day simple moving average of $41.67.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AGIO has been the topic of a number of research reports. HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.